Subscribe to press release roundup

To regularly receive important releases about Endeavour Vision and portfolio companies

Title *
First name *
Last name *
E-mail *
April 6, 2017
Molecular Partners discloses change in shareholder base

 Long-term venture capital investors holding reduced to 28% of share capital
 Private investors acquired shares from venture capitalist investors in secondary block trades

Zurich-Schlieren, April 6, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage
biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today
reported changes in ownership based on disclosure notifications received according to Article 120
of the Swiss Financial Market Infrastructure Act. According to such disclosure notifications, three
investors crossed the following thresholds on April 5, 2017: Index Ventures Funds fell below 10%
to 8.18%; Essex Woodlands Health Ventures Funds, below 10% to 7.82%, and Johnson & Johnson
Innovation, below 5% to 4.25%. Private investors acquired shares from venture capitalist investors
in secondary block trades.

“We are pleased to report the continued evolution of our shareholder base as we advance
innovative DARPin® therapies to benefit patients. We are grateful for the continued support of
long-term investors who recognized the clinical and commercial potential of our DARPin® platform
more than a decade ago,” said Patrick Amstutz, acting Chief Executive Officer of Molecular
Partners. “The natural rotation of our shareholder base enables the continued progress of
Molecular Partners as we approach multiple value inflection points in 2018 and beyond, including
the anticipated one-year readout of the efficacy data from two Phase 3 clinical trials of abicipar,
our lead compound for wet age-related macular degeneration being developed in partnership with
Allergan and the initial readout of our proprietary MP0250 study in multiple myeloma and an
additional solid tumor indication.”

Financial Calendar
April 13, 2017 Publication of Invitation to Annual General Meeting 2017
May 4, 2017 Q1 2017 Management Statement
May 11, 2017 Annual General Meeting
August 30, 2017 Publication of 2017 Half-year Results
October 26, 2017 Q3 2017 Management Statement

About Molecular Partners AG
Molecular Partners AG is a clinical-stage biopharmaceutical company developing a new class of
therapies known as DARPin® therapies. With a management team that includes many of the
founding scientists, the company continues to attract talented individuals who share the passion
to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in
various stages of clinical and preclinical development and several more in the research stage, with
a current focus on ophthalmology and oncology. The company establishes research and
development partnerships with leading pharmaceutical companies and is backed by established
biotech investors.
For more information regarding Molecular Partners AG, go to:


© Endeavour Vision SA 2006-2017 Terms & Conditions